Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors

Abstract

pCR is associated with better outcome regardless of HR status in breast cancer patients who receive PC.

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

“…In patients with luminal tumors the pCR in the luminal B group including also HER2 positive cases, was higher than in the luminal A group. Similar results were seen by Guarneri et al [11] in a pooled analysis of multiple neoadjuvant trials with different chemotherapy regimens. The pCR rate in the HR+ and HER2 positive tumors was significantly higher than for those with an HR+ and HER2 negative tumor (15% vs. 6%).…”

Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902

“…One of the oldest (validated) prognostic and predictive factor is the ER. It was demonstrated that pCR is more likely to occur in patients with ER negative than ER positive disease [30][31][32][33]. Therefore, preoperative chemotherapy may not be the most appropriate preoperative approach for patients with ER positive disease.…”

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

“…Patients with an endocrine responsive disease have the opportunity to respond to proper endocrine therapies and consequently to present an event several years after surgery. In fact, Guarneri et al [6] showed that in the preoperative setting patients with hormone receptor (HR) positive tumors tended to have better PFS compared with patients with HRnegative breast cancer until just after 100 months after their response assessment. The curves then crossed, and patients with HR-positive tumors tended to have worse PFS compared with patients with HR-negative tumors.…”

“…It was recently shown that the pathological complete remission (pCR) rate was significantly higher following PCT for patients with tumors not expressing estrogen (ER) and progesterone receptor (PgR), compared with the receptor positive cohort [4][5][6]. Regardless of the significantly higher incidence of pCR for patients with ER and PgR absent disease, the 5-year disease-free survival (DFS) was significantly worse for this cohort compared with the low/positive expression cohort in several studies [5][6][7][8]. In these studies analyses were performed based on a so-called 'receptor-negative grouping', which combines receptor-absent disease with that expressing low receptor levels, and 'receptor positive grouping' which combines all patients with tumors expressing ER and/or PgR in C10% of the cells.…”